Johnson & Johnson $JNJ Shares Sold by Pinnacle Associates Ltd.

Pinnacle Associates Ltd. reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.2% during the third quarter, Holdings Channel reports. The institutional investor owned 1,653,904 shares of the company’s stock after selling 3,008 shares during the period. Johnson & Johnson comprises about 4.9% of Pinnacle Associates Ltd.’s portfolio, making the stock its largest holding. Pinnacle Associates Ltd.’s holdings in Johnson & Johnson were worth $437,855,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Sulzberger Capital Advisors Inc. increased its position in shares of Johnson & Johnson by 3.4% during the third quarter. Sulzberger Capital Advisors Inc. now owns 2,481 shares of the company’s stock worth $657,000 after acquiring an additional 81 shares in the last quarter. Uncommon Cents Investing Inc raised its holdings in shares of Johnson & Johnson by 1.5% in the 3rd quarter. Uncommon Cents Investing Inc now owns 31,185 shares of the company’s stock worth $8,256,000 after acquiring an additional 448 shares during the last quarter. Harfst & Associates Inc. lifted its position in Johnson & Johnson by 0.6% in the 3rd quarter. Harfst & Associates Inc. now owns 10,213 shares of the company’s stock valued at $2,704,000 after acquiring an additional 61 shares in the last quarter. Oath Planning LLC lifted its position in Johnson & Johnson by 21.2% in the 3rd quarter. Oath Planning LLC now owns 1,535 shares of the company’s stock valued at $407,000 after acquiring an additional 268 shares in the last quarter. Finally, Sensible Money LLC lifted its position in Johnson & Johnson by 14.8% in the 3rd quarter. Sensible Money LLC now owns 988 shares of the company’s stock valued at $262,000 after acquiring an additional 127 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

JNJ stock opened at $267.67 on Friday. The firm has a market cap of $645.05 billion, a PE ratio of 40.56, a P/E/G ratio of 2.55 and a beta of 0.21. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The business has a 50 day moving average of $265.57 and a 200-day moving average of $250.11. Johnson & Johnson has a 12-month low of $184.66 and a 12-month high of $281.07.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. The company had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a return on equity of 31.54% and a net margin of 16.20%. Johnson & Johnson’s revenue was up 5.9% on a year-over-year basis. During the same period last year, the business posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, sell-side analysts expect that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 81.21%.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Citigroup boosted their price objective on Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a report on Monday, October 5th. Stifel Nicolaus set a $260.00 price objective on shares of Johnson & Johnson in a report on Wednesday, July 15th. Morgan Stanley reduced their target price on shares of Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating for the company in a research note on Thursday, October 15th. Argus set a $300.00 target price on shares of Johnson & Johnson in a report on Wednesday, July 29th. Finally, UBS Group set a $270.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 14th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $275.92.

Insider Activity

In other news, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. The trade was a 56.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Elizabeth Forminard sold 15,918 shares of the business’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the transaction, the executive vice president directly owned 16,994 shares in the company, valued at $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 64,515 shares of company stock valued at $17,271,766 in the last ninety days. 0.16% of the stock is currently owned by insiders.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Positive sector rotation: JNJ is benefiting from fresh demand for defensive healthcare stocks, alongside gains in Procter & Gamble and Coca-Cola. Investors appear to be favoring companies with relatively stable demand and cash flows amid broader market pressure. Procter & Gamble Jumps as Defensive Buyers Enter
• Positive Sentiment: Medical-device progress: Johnson & Johnson reported real-world data for its VARIPULSE Pro platform and 12-month outcomes for the OMNYPULSE platform in atrial-fibrillation treatment. The results could support adoption of its electrophysiology portfolio and provide another growth avenue beyond pharmaceuticals. Johnson & Johnson Reports VARIPULSE and OMNYPULSE Data
• Positive Sentiment: Drug growth and guidance: Recent coverage highlights stronger pharmaceutical performance and Johnson & Johnson’s higher 2026 outlook, with projected sales of approximately $101.2 billion at the midpoint. The company also maintains a 64-year record of annual dividend increases, reinforcing its appeal to income-focused investors. Johnson & Johnson Drugs Lift Guidance
• Neutral Sentiment: Mixed business outlook: One business is advancing strongly while another has stalled, leaving investors focused on whether new growth can justify JNJ’s premium valuation relative to competitors such as Merck and AbbVie. JNJ Stock Has a New Growth Story
• Negative Sentiment: Analyst caution and valuation risk: Erste Group Bank downgraded JNJ from “buy” to “hold.” Commentary also notes that the stock’s elevated valuation could constrain returns, particularly as Treasury yields near 5% make government bonds more competitive with dividend stocks. Erste Group Bank Ratings

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.